Primary disease(s) |
Source |
Study design |
Quality rating |
No. of patients |
Dosage |
Controlled group |
Outcome measure |
Outcome |
Adult-onset Still’s Disease |
Kaneko et al.
2018[25]
|
Randomized controlled trial |
1 |
27 |
8 mg/kg/4 weeks for 40 weeks |
Placebo |
Systemic feature score,
glucocorticoid dose |
The least squares means for change in systemic
feature score at week 12 were 4.1 in the tocilizumab group and 2.3 in
the placebo group (p=0.003). The dose of glucocorticoids at week 12
decreased by 46.2% in the tocilizumab group and 21.0% in the placebo
group (p=0.017). |
Sjögren’s Syndrome |
Felten et al.
2020[26]
|
Randomized controlled trial |
1 |
110 |
8 mg/kg/4 weeks for 6 months |
Placebo |
ESSDAI score |
ESSDAI score
decreased in tocilizumab group |
Systemic Scleroderma
|
Khanna et al. 2016[27]
|
Randomized controlled trial
|
1
|
87
|
162 mg/
week for 48 weeks
|
Placebo
|
mRSS, VAS score, FACIT-fatigue scores.
|
mRSS improved, VAS score and FACIT-fatigue scores had favourable
response.
|
Neuromyelitis Optic Spectrum Disease |
Zhang et
al.2020[28]
|
Randomized controlled trial |
1 |
118 |
8 mg/kg/4 weeks for 60 weeks |
Azathioprine |
Median time to the
first relapse |
The median time to first relapse was also longer in the
tocilizumab group than the azathioprine group |
Takayasu Arteritis
|
Nakaoka et al. 2020[29]
|
Randomized controlled trial
|
1
|
36
|
162 mg/
week for 96 weeks or longer
|
Placebo
|
Mean 36-Item Short Form Health Survey, glucocorticoid dose
|
Mean 36-Item Short Form Health Survey 7 of 8 domain scores were
clinically improved from baseline and maintained over 96 weeks. The dose
of glucocorticoid was less than a half before treatment.
|
Systemic Lupus Erythematosus
|
Lllei et al. 2018[30]
|
Open-label controlled trial
|
2
|
16
|
2 mg/kg [n=4],
4 mg/kg [n=6],
8 mg/kg [n=6],
for 12 weeks
|
Different doseage group
|
SELENA-SLEDAI score
|
Anti-dsDNA antibody levels decreased, IgG levels decreased, circulating
plasma cells decreased
|
Relapsing Polychondritis |
Moulis et al.
2018[31]
|
Cohort study |
3 |
43 |
Not clear |
TNF
inhibitors, anakinra, rituximab, abatacept |
Complete response (CR). |
Tocilizumab was highly effective for almost all
features
of RP and decreased doseage of glucosteroid
significantly.
|
Dermatomyositis |
Kondo et al. 2014[32]
|
Case Report |
5 |
1 |
Not clear |
N/A |
Serum CK level |
Serum CK level
decreased |
Psoriatic Arthritis
|
Madureira et al.[33]
|
Case series
|
5
|
3
|
8 mg/kg/4 weeks
(Case 1:
12 months; Case 2:
48 months; Case 3:
37 months)
|
Case 1,2:
adalimumab
Case 3:
rituximab
|
PASI, CRP,
DAS,
TJC,
SJC,
HAQ
|
All measure items decreased
|
Systemic Vasculitis |
Sakai et al.
2017[34]
|
Case series |
5 |
2 |
8 mg/kg/4 weeks
for 2 weeks |
N/A |
Prednisolone dose |
Prednisolone dose decreased
significantly |
Quality rating scheme is modified from the Oxford Centre of
Evidence-Based Medicine for ratings of individual studies: (1) properly
powered and conducted randomized clinical trial; systematic review with
meta-analysis; (2) well-designed controlled trial without randomization;
prospective comparative cohort trial; (3) case-control studies;
retrospective cohort study; (4) case series with or without
intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |
Quality rating scheme is modified from the
Oxford Centre of Evidence-Based Medicine for ratings of individual
studies: (1) properly powered and conducted randomized clinical trial;
systematic review with meta-analysis; (2) well-designed controlled trial
without randomization; prospective comparative cohort trial; (3)
case-control studies; retrospective cohort study; (4) case series with
or without intervention; cross-sectional study; (5) opinion of respected
authorities; case reports. |